Black Diamond Therapeutics
BDTX
87 hedge funds and large institutions have $64.1M invested in Black Diamond Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 19 closing their positions.
0.91% less ownership
Funds ownership: 64.05% → 63.14% (-0.91%)
8% less funds holding
Funds holding: 95 → 87 (-8)
12% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 26
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
48% less capital invested
Capital invested by funds: $124M → $64.1M (-$59.5M)
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $192K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.03M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$475K |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$403K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$392K |
| 5 |
Two Sigma Investments
New York
|
+$389K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.45M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.23M |
| 3 |
Morgan Stanley
New York
|
-$1.02M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$621K |
| 5 |
Renaissance Technologies
New York
|
-$441K |
BDTX Hedge Fund Activity: Q1 2022 in Review
87 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2022, worth a combined $64.1M — down 48% from $124M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of BDTX and 11 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 23 added.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $1.03M. The largest seller was Millennium Management, exiting entirely with an estimated $1.45M sold.
- 87 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2022, down from 95 in Q4 2021.
- Funds reported $64.1M of Black Diamond Therapeutics stock for Q1 2022, down 48% quarter-over-quarter.
- 11 funds opened new Black Diamond Therapeutics positions in Q1 2022 and 19 closed out, a net change of -8 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.03M added.
- The largest Black Diamond Therapeutics seller in Q1 2022 was Millennium Management, an estimated $1.45M sold.
Based on aggregated 13F filings for Q1 2022.